ClinicalTrials.gg
RecruitingNCT04949633OPICUpdated Jul 27, 2026

Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

A Phase 3 interventional study of Prostaglandins and Oxytocin in Cervical Ripening and Unfavorable Cervix, sponsored by University Hospital, Tours. Recruiting at 14 sites in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by University Hospital, Tours · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,494
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Twenty-two percent of deliveries in France are induced. In cases where labor is induced and cervix is unfavorable, cervical ripening prior oxytocin administration is advised in order to reduce the risk of cesarean delivery. Cervical ripening agents, pharmacological (prostaglandins) or mechanical are administered during 24 hours. After 24 hours, most women will be either delivered or in labor but 25% of women will require further induction of labor. For 16% of women who undergo cervical ripening, whatever the cervical ripening method, the cervix remains unchanged after 24 hours. The management of these women is not consensual and depends on the maternity unit where women are cared for.

This study seeks to identify the most appropriate strategy for the management of women with an unfavorable cervix after 24 hours of cervical ripening, a strategy which would be associated with the lowest maternal and perinatal morbidity but also with the best maternal satisfaction. Because both strategies are practiced in France, the trial would compare: induction of labor with oxytocin and repeated cervical ripening. The aim is to show that repeating cervical ripening is an unnecessary procedure. And more specifically that oxytocin administration is not associated with a higher caesarean delivery rate and that it reduces the time to delivery in comparison with cervical ripening with prostaglandins.

Read the detailed description

Twenty-two percent of deliveries in France are induced. In cases where labor is induced and cervix is unfavorable, cervical ripening prior oxytocin administration is advised in order to reduce the risk of cesarean delivery. Cervical ripening agents, pharmacological (prostaglandins) or mechanical are administered during 24 hours. After 24 hours, most women will be either delivered or in labor but 25% of women will require further induction of labor. For 16% of women who undergo cervical ripening, whatever the cervical ripening method, the cervix remains unchanged after 24 hours. The management of these women is not consensual and depends on the maternity unit where women are cared for. In some units, women are admitted into labor ward for induction of labor with oxytocin. Elsewhere cervical ripening is repeated in order to obtain a favorable cervix and to reduce the risk of caesarean delivery.

This study seeks to identify the most appropriate strategy for the management of women with an unfavorable cervix after 24 hours of cervical ripening, a strategy which would be associated with the lowest maternal and perinatal morbidity but also with the best maternal satisfaction. Because both strategies are practiced in France, the trial would compare: induction of labor with oxytocin and repeated cervical ripening. The policy of induction of labor with oxytocin, being the simpler strategy, would be acceptable if it did not lead to a substantially proportion of women with caesarean deliveries compared with a second cervical ripening. This multicenter non inferiority randomized trial will recruit women with an unfavorable cervix (bishop score ≤ 6) after 24 hours of cervical ripening (pharmacological or mechanical) and randomize them to either induction of labor with oxytocin or to a second cervical ripening with prostaglandins. The aim is to show that repeating cervical ripening is an unnecessary procedure. And more specifically that oxytocin administration is not associated with a higher caesarean delivery rate and that it reduces the time to delivery in comparison with cervical ripening with prostaglandins.

02

Conditions studied

  • Cervical Ripening
  • Unfavorable Cervix

Keywords

  • cervical ripening
  • oxytocin
  • prostaglandin
  • cesarean delivery
03

In context

Lead sponsor

University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant woman
  • ≥ 18 years old
  • With a singleton cephalic pregnancy
  • ≥37+0 weeks of gestation
  • Gestational age estimated from the first trimester ultrasound (realized between 11+0 and 13+6 weeks of gestation)
  • With a medical indication of labor with a previous pharmacological or mechanical cervical ripening of 24 hours
  • Bishop score ≤ 6 at inclusion (unfavorable cervix)
  • French health insurance policy holder
  • Written

Exclusion criteria

Exclusion Criteria:

  • Any measures of legal protection
  • Prior caesarean section or uterine scar
  • to a vaginal delivery
  • Foetus with suspected severe congenital abnormalities
  • Pathological foetal heart rate
  • Contra-indications to ANGUSTA® (oral misoprostol, cervical ripening agent)
  • Contra-indications to PROPESS® (vaginal slow releasing system of dinoprostone, cervical ripening agent)
  • Contra-indications to PROSTINE® (vaginal gel of dinoprostone, cervical ripening agent)
  • Contra-indications for using oxytocin
  • Woman in labor
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,494 participants (estimated)

Study arms

  • Experimental
    Induction of labor

    women randomized in the experimental group will be admitted to the labor ward to undergo induction of labor with intra-veinous oxytocin and early amniotomy. Oxytocin will be administered according to the French guidelines for induction of labor. Maximum oxytocin used should not exceed 10 UI.

    Drug: Oxytocin

  • Active comparator
    Second cervical ripening

    women randomized in the control group will undergo a second cervical ripening lasting a maximum of 24 hours with either: * Vaginal slow releasing system of dinoprostone PROPESS® which is inserted in the vagina, against the cervix and left in place during 24 hours. * Oral misoprostol (ANGUSTA®) 25 µg every 2 hours, 8 times (maximum dosage should not exceed 200µg). Tablets will be given one at the time by midwives. * Vaginal gel of dinoprostone (2 mg PROSTINE®) every 6 hours, maximum dose of 6 mg. The choice of the cervical ripening agent will depend of the local protocol of the participating maternity unit. The choice between ANGUSTA®, PROPESS® and PROSTINE® will be made by investigators of each participating unit at the beginning of the trial. At the end of the second cervical ripening procedure women not in labor will be transferred to the labor ward for induction of labor with oxytocin.

    Drug: Prostaglandins · Drug: Oxytocin

Interventions

  • Second cervical ripening lasting a maximum of 24 hours

  • Induction of labor with oxytocin.

06

What researchers measure

Primary outcomes

  1. Cesarean delivery rate

    The main outcome is the rate of caesarean delivery, whatever the indication of the caesarean delivery

    Time frame: Up to 2 days after intervention

Secondary outcomes

  1. Time from intervention to delivery in hours

    Time frame: Up to 2 days after intervention

  2. The proportion of women who delivered within 12 hours of the intervention

    Time frame: Up to 12 hours after intervention

  3. Maternal satisfaction, assessed with the self administered ACE Questionnaire for Assessing Childbirth Experience (QACE)

    Time frame: 1 month

  4. The proportion of women who require induction with oxytocin (for women in the control group)

    Time frame: Up to 2 days after intervention

  5. The indications of caesarean in case of caesarean delivery

    Time frame: Up to 2 days after intervention

  6. The proportion of women with an instrumental delivery

    Time frame: Up to 2 days after intervention

  7. The indications for the use of instruments in case of instrumental delivery

    Time frame: Up to 2 days after intervention

  8. The proportion of women suspected of per-partum infection

    Time frame: Up to 2 days after intervention

  9. The proportion of women with post-partum haemorrhage

    Time frame: Up to 1 day after delivery

  10. The proportion of women with severe Post-partum haemorrhage

    Time frame: Up to 2 days after intervention

  11. The proportion of women with anal sphincter injury at delivery

    Time frame: Up to 2 days after intervention

  12. The proportion of women who need blood transfusion

    Time frame: Up to 2 days after intervention

  13. The proportion of women who need for antibiotics

    Time frame: Up to 2 days after intervention

  14. The proportion of women admitted to intensive care unit

    Time frame: Up to 2 days after intervention

Other outcomes

  1. Number and rate of children with an Apgar score under 7

    Time frame: Up to 2 days after intervention

  2. Number and rate of children with neonatal acidosis defined as umbilical arterial pH <7,00

    Time frame: Up to 2 days after intervention

  3. Number and rate of children with early neonatal infection

    Time frame: Up to 7 days after delivery

  4. Number and rate of children admitted in an intensive care unit

    Time frame: Up to 7 days after delivery

  5. Proportion of incremental cost-effect pairs

    Health economic outcome

    Time frame: Up to 8 weeks

07

Study locations

8 of 14 sites recruiting
  • Gynaecology-obstetrics, University Hospital, Angers
    Angers, 49033, France
    Recruiting
    • Guillaume LEGENDRE, MD-PhD · Contact
    • Guillaume LEGENDRE, MD-PhD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Bordeaux
    Bordeaux, 33076, France
    Terminated

    Not enrolling at this site.

  • Gynaecology-obstetrics, University Hospital, Brest
    Brest, 29609, France
    Recruiting
    • Jordan POZZY, MD · Contact
    • Jordan POZZI, MD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Clermont-Ferrand
    Clermont-Ferrand, 63001, France
    Terminated

    Not enrolling at this site.

  • Gynaecology-obstetrics, Hospital St Joseph, Marseille
    Marseille, 13008, France
    Terminated

    Not enrolling at this site.

  • Gynaecology-obstetrics, University Hospital, Nancy
    Nancy, 54000, France
    Recruiting
    • Charline BERTHOLDT, MD · Contact
    • Charline BERTHOLDT, MD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Nantes
    Nantes, 44093, France
    Recruiting
    • Norbert WINER, MD-PhD · Contact
    • Norbert WINER, MD-PhD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Orléans
    Orléans, 45100, France
    Recruiting
    • Floranne MEUNIER, MD · Contact
    • Floranne MEUNIER, MD · Principal investigator
  • Gynaecology-obstetrics, Port Royal Maternity Hospital, Paris
    Paris, 75014, France
    Recruiting
    • François GOFFINET, MD · Contact
    • François GOFFINET, MD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Poitiers
    Poitiers, 86000, France
    Terminated

    Not enrolling at this site.

  • Gynaecology-obstetrics, Hospital, Pontoise
    Pontoise, 95300, France
    Not yet recruiting
    • Christophe PONCELET, MD-PhD · Contact
    • Christophe PONCELET, MD-PhD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Saint Etienne
    Saint-Etienne, 42270, France
    Recruiting
    • Tiphaine BARJAT, MD · Contact
    • Tiphaine BARJAT, MD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Strasbourg
    Strasbourg, 67000, France
    Not yet recruiting
    • Virginie COLLIN-BUND, MD · Contact
    • Virginie COLLIN-BUND, MD · Principal investigator
  • Gynaecology-obstetrics, University Hospital, Tours
    Tours, 37044, France
    Recruiting
    • Franck PERROTIN, MD-PhD · Contact
    • Franck PERROTIN, MD-PhD · Principal investigator
08

References and documents

Publications

  • De Berti M, Le Gouge A, Monmousseau F, Gallot D, Sentilhes L, Winer N, Legendre G, Desbriere R, Girault A, Pozzi J, Gachon B, Barjat T, Perrotin F, Brunet-Houdard S, Diguisto C; Groupe de Recherche en Gynecologie Obstetrique. Oxytocin versus prostaglandins for labour Induction of women with an unfavourable cervix after 24 hours of cervical ripening (OPIC): protocol for an open multicentre randomised non-inferiority trial. BMJ Open. 2023 Apr 17;13(4):e058282. doi: 10.1136/bmjopen-2021-058282. PubMed 37068892 ↗

Individual participant data

Plan to share: Yes — Individual participant data after de-identification can be obtained by contacting the corresponding author

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available immediately following publication and ending in 5 years

Access criteria: Contact with the corresponding author

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Sep 2027, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jul 2, 2021
StartActual
Sep 28, 2021
Primary completionEst.
Sep 2027
CompletionEst.
Nov 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04949633
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Sep 28, 2021
Primary completion
Sep 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Caroline DIGUISTO, MD
Contact
carolinediguisto@gmail.com
02 47 47 47 39 ext. +33
Caroline DIGUISTO, MD
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion